Lipocine Shares USPTO Decision in Interference Case

- September 21st, 2017

Lipocine announced that the Patent Trial and Appeal Board of the United States Patent and Trademark Office issued a Motions Decision based on each party’s motions in an interference case.

Lipocine (NASDAQ:LPCN) announced that the Patent Trial and Appeal Board of the United States Patent and Trademark Office issued a Motions Decision based on each party’s motions in an interference case.
As quoted in the press release:

Patent Interference No. 106,045, between Clarus Therapeutics, Inc. (“Clarus”) U.S. Patent No. 8,828,428 (the “Clarus ‘428 Patent”), and Lipocine Inc. (“Lipocine”), U.S. Patent Application No. 14/713,692 (the “Lipocine ‘692 Application”).

The PTAB granted Lipocine’s motion to deny Clarus’ previously accorded priority date for the ‘428 Patent. Therefore, Clarus has a new priority date of April 16, 2014 for the Clarus ‘428 patent.  The PTAB also granted Clarus’ motion to deny Lipocine’s accorded priority date.

Click here to read the full press release.

Source: globenewswire.com

Leave a Reply